Fumagillin Shortage: How to Treat Enterocytozoon bieneusi Microsporidiosis in Solid Organ Transplant Recipients in 2024?
Transplant International · 2024
DOI: 10.3389/ti.2024.13518 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplant International, 2024. Verfasst von Cyril Garrouste und 56 weiteren Autor:innen. Beteiligte Einrichtung: Service de Néphrologie, CHU Clermont-Ferrand, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Cyclohexanes, Fatty Acids, Unsaturated, Microsporidiosis, Sesquiterpenes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Intestinal microsporidiosis caused by Enterocytozoon bieneusi is an opportunistic infection that especially affects solid organ transplant (SOT) recipients. Management revolves around tapering the immunosuppressive regimen and/or using a specific anti-microsporidia treatment, but only fumagillin has demonstrated efficacy for treatment of this infection. Since fumagillin has been commercially discontinued, nitazoxanide is increasingly being used in this indication. We aimed to describe therapeutic management of E. bieneusi infections in this context. We conducted a French nationwide observational retrospective study on reported cases of E. bieneusi infections in SOT recipients. We identified 154 cases: 64 (41.6%) were managed by simply modifying the immunosuppressive regimen, 54 (35.1%) were given fumagillin, and 36 (23.4%) were given nitazoxanide. Clinical remission rate ranged from 77.8% to 90.7% and was not significantly different between therapeutic strategies but tended to be lower with nitazoxanide. Stool negativization rate was highest with fumagillin (91.7%) and lowest with nitazoxanide (28.6%). Relapses occurred in 6.9% of cases and were more frequent with nitazoxanide (14.3%). This study shows that tapering immunosuppression can result in a satisfactory remission rate but is sometimes accompanied by relapses. Nitazoxanide had limited effectiveness, whereas fumagillin had good results that provide a solid rationale for bringing fumagillin back to market. Trial Registration Number ClinicalTrials.gov ID: NCT05417815.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Néphrologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.
- Service de Parasitologie-Mycologie, 3IHP, Inserm U1071, M2iSH, USC-INRAE 1382, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France.
- Centre National de Référence des Cryptosporidioses, Microsporidies et Autres Protozooses Digestives, Laboratoire Associé de Clermont-Ferrand, Clermont-Ferrand, France.
- Service de Parasitologie-Mycologie, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), CNRS UMR5051, INSERM UMR1291, Université Toulouse III Paul Sabatier, CHU Toulouse, Toulouse, France.
- Service de Néphrologie, CHU Toulouse, Toulouse, France.
- Service de Parasitologie-Mycologie, ToxEMAC-ABTE, Université de Normandie Unicaen, CHU Caen, Caen, France.
Zitieren
APA
Garrouste, C., Poirier, P., Uro-Coste, C., Iriart, X., Kamar, N., Bonhomme, J., Calvar, E., Le Gal, S., Lanfranco, L., Autier, B., Rakoff, L., Durieux, M. F., Danthu, C., Morio, F., Deltombe, C., Moreno-Sabater, A., Ouali, N., Costa, D., Bertrand, D., …, & Nourrisson, C. (2024). Fumagillin Shortage: How to Treat Enterocytozoon bieneusi Microsporidiosis in Solid Organ Transplant Recipients in 2024?. Transplant International. https://doi.org/10.3389/ti.2024.13518
Vancouver
Garrouste C, Poirier P, Uro-Coste C, Iriart X, Kamar N, Bonhomme J, et al. Fumagillin Shortage: How to Treat Enterocytozoon bieneusi Microsporidiosis in Solid Organ Transplant Recipients in 2024?. Transplant International. 2024. doi:10.3389/ti.2024.13518
BibTeX
@article{Garrouste2024,
author = {Garrouste, Cyril and Poirier, Philippe and Uro-Coste, Charlotte and Iriart, Xavier and Kamar, Nassim and Bonhomme, Julie and Calvar, Eve and Le Gal, Solène and Lanfranco, Luca and Autier, Brice and Rakoff, Lucien and Durieux, Marie-Fleur and Danthu, Clément and Morio, Florent and Deltombe, Clément and Moreno-Sabater, Alicia and Ouali, Nacera and Costa, Damien and Bertrand, Dominique and Chesnay, Adélaïde and Gatault, Philippe and Rabodonirina, Meja and Morelon, Emmanuel and Dumortier, Jérôme and Sitterlé, Emilie and Scemla, Anne and Hamane, Samia and Cachera, Laurène and Damiani, Céline and Poulain, Coralie and L'Ollivier, Coralie and Moal, Valérie and Delhaes, Laurence and Kaminski, Hannah and Cateau, Estelle and Ecotière, Laure and Brunet, Julie and Caillard, Sophie and Valot, Stéphane and Tinel, Claire and Argy, Nicolas and Raimbourg, Quentin and Robert, Marie Gladys and Noble, Johan and Boignard, Aude and Botterel, Françoise and Matignon, Marie and Bellanger, Anne-Pauline and Crépin, Thomas and Leroy, Jordan and Lionet, Arnaud and Debourgogne, Anne and Nicolas, Muriel and Claudéon, Joëlle and Moniot, Maxime and Lambert, Céline and Nourrisson, Céline},
title = {Fumagillin Shortage: How to Treat Enterocytozoon bieneusi Microsporidiosis in Solid Organ Transplant Recipients in 2024?},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.13518}
}
EUVIMED